{
    "organizations": [],
    "uuid": "ef7e1856c5857230ec805d749c38f1648cc114e6",
    "author": "",
    "url": "https://www.reuters.com/article/brief-rhythm-pharmaceuticals-announces-p/brief-rhythm-pharmaceuticals-announces-progress-in-clinical-development-of-setmelanotide-idUSFWN1OZ0N8",
    "ord_in_thread": 0,
    "title": "BRIEF-Rhythm Pharmaceuticals Announces Progress In Clinical Development Of Setmelanotide",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 4, 2018 / 5:44 PM / in 6 minutes BRIEF-Rhythm Pharmaceuticals Announces Progress In Clinical Development Of Setmelanotide Reuters Staff 1 Min Read \nJan 4 (Reuters) - Rhythm Pharmaceuticals Inc: \n* RHYTHM PHARMACEUTICALS ANNOUNCES PROGRESS IN CLINICAL DEVELOPMENT OF SETMELANOTIDE FOR TREATMENT OF RARE GENETIC DISORDERS OF OBESITY \n* RHYTHM PHARMACEUTICALS - SETMELANOTIDE GRANTED ORPHAN DRUG DESIGNATION FOR TREATMENT OF LEPTIN RECEPTOR (LEPR) DEFICIENCY OBESITY \n* RHYTHM PHARMACEUTICALS - FINALIZED PROTOCOL FOR PIVOTAL PHASE 3 CLINICAL TRIAL IN PRO-OPIOMELANOCORTIN (POMC) DEFICIENCY OBESITY \n* RHYTHM PHARMACEUTICALS - CONFIRMS PLANS TO FILE NDA WITH FDA BASED ON ONE-YEAR DATA FROM 10 PATIENT COHORT IN POMC PHASE 3 CLINICAL TRIAL Source text for Eikon: Further company coverage:",
    "published": "2018-01-04T19:44:00.000+02:00",
    "crawled": "2018-01-04T20:06:19.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "pharmaceutical",
        "announces",
        "progress",
        "clinical",
        "development",
        "setmelanotide",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "rhythm",
        "pharmaceutical",
        "inc",
        "rhythm",
        "pharmaceutical",
        "announces",
        "progress",
        "clinical",
        "development",
        "setmelanotide",
        "treatment",
        "rare",
        "genetic",
        "disorder",
        "obesity",
        "rhythm",
        "pharmaceutical",
        "setmelanotide",
        "granted",
        "orphan",
        "drug",
        "designation",
        "treatment",
        "leptin",
        "receptor",
        "lepr",
        "deficiency",
        "obesity",
        "rhythm",
        "pharmaceutical",
        "finalized",
        "protocol",
        "pivotal",
        "phase",
        "clinical",
        "trial",
        "pomc",
        "deficiency",
        "obesity",
        "rhythm",
        "pharmaceutical",
        "confirms",
        "plan",
        "file",
        "nda",
        "fda",
        "based",
        "data",
        "patient",
        "cohort",
        "pomc",
        "phase",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}